keyword
https://read.qxmd.com/read/38629258/off-label-prescribing-of-immune-checkpoint-inhibitor-therapy-at-a-single-pediatric-cancer-center
#1
JOURNAL ARTICLE
Ajami Gikandi, Susan N Chi, Kee Kiat Yeo, Allison F O'Neill, David S Shulman, Steven G DuBois, Natalie B Collins
BACKGROUND: Immune checkpoint inhibitors (ICI) have improved outcomes in a variety of adult cancers and are prescribed with increasing frequency across oncology. However, patterns of off-label use of ICI in pediatrics remain unclear. METHODS: This is a single-institution, retrospective cohort study evaluating off-label ICI use in pediatric and young adult patients with cancer treated at our institution from 2014 to 2022. Response was based on clinician assessment derived from clinical records...
April 2024: Cancer Medicine
https://read.qxmd.com/read/38627882/event-free-survival-in-relapsed-and-refractory-rhabdomyosarcoma-treated-on-cooperative-group-phase-ii-trials-a-report-from-the-children-s-oncology-group
#2
JOURNAL ARTICLE
Jonathan Metts, Wei Xue, Zhengya Gao, Sapna Oberoi, Aaron R Weiss, Rajkumar Venkatramani, Douglas J Harrison
BACKGROUND: Novel therapies are needed for relapsed and refractory rhabdomyosarcoma (RRMS). Phase II clinical trials in RRMS have typically utilized radiologic response as the primary activity endpoint, an approach that poses several limitations in RRMS. In this analysis, we aimed to estimate an event-free survival (EFS) endpoint for RRMS that could be used as a benchmark for future studies. PROCEDURE: We performed a retrospective study of patients with RRMS enrolling on 13 single-agent phase II Children's Oncology Group and legacy group trials from 1997 to 2016...
April 16, 2024: Pediatric Blood & Cancer
https://read.qxmd.com/read/38626849/the-involvement-of-ros-regulated-programmed-cell-death-in-hepatocellular-carcinoma
#3
REVIEW
Hanchen Cai, Ziqi Meng, Fujun Yu
Reactive oxidative species (ROS) is a crucial factor in the regulation of cellular biological activity and function, and aberrant levels of ROS can contribute to the development of a variety of diseases, particularly cancer. Numerous discoveries have affirmed that this process is strongly associated with "programmed cell death (PCD)," which refers to the suicide protection mechanism initiated by cells in response to external stimuli, such as apoptosis, autophagy, ferroptosis, etc. Research has demonstrated that ROS-induced PCD is crucial for the development of hepatocellular carcinoma (HCC)...
April 14, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38626848/the-crosstalk-between-oncogenic-signaling-and-ferroptosis-in-cancer
#4
REVIEW
Qianghu Pang, Zhirou Tang, Lianxiang Luo
Ferroptosis, a novel form of cell death regulation, was identified in 2012. It is characterized by unique features that differentiate it from other types of cell death, including necrosis, apoptosis, autophagy, and pyroptosis. Ferroptosis is defined by an abundance of iron ions and lipid peroxidation, resulting in alterations in subcellular structures, an elevation in reactive oxygen species (ROS), a reduction in glutathione (GSH) levels, and an augmentation in Fe (II) cytokines. Ferroptosis, a regulated process, is controlled by an intricate network of signaling pathways, where multiple stimuli can either enhance or hinder the process...
April 16, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38625410/platinum-based-adjuvant-chemoradiotherapy-versus-adjuvant-radiotherapy-in-patients-with-head-and-neck-adenoid-cystic-carcinoma
#5
JOURNAL ARTICLE
Zichen Qiu, Zheng Wu, Xiong Zhou, Minchuan Lin, Yong Su, Yalan Tao
PURPOSE: The objective of the study was to assess the effectiveness and toxicity of platinum-based adjuvant chemoradiotherapy (POCRT) in comparison to postoperative radiotherapy (PORT) in patients with head and neck adenoid cystic carcinoma (HNACC). MATERIALS AND METHODS: This retrospective study analyzed patients diagnosed with HNACC at our center between January 2010 and April 2020. A 1:1 propensity score matching method was used to create a matched cohort. RESULTS: In this study, 206 patients were analyzed, with 147 patients (71...
April 16, 2024: Journal of Cancer Research and Clinical Oncology
https://read.qxmd.com/read/38625382/-clinical-acute-and-emergency-medicine-curriculum-focus-on-internal-medicine-recommendations-for-advanced-training-in-internal-medicine-in-the-emergency-department
#6
REVIEW
Hans-Jörg Busch, Sebastian Wolfrum, Guido Michels, Matthias Baumgärtel, Klaus-Friedrich Bodmann, Michael Buerke, Volker Burst, Philipp Enghard, Georg Ertl, Wolf Andreas Fach, Frank Hanses, Hans Jürgen Heppner, Carsten Hermes, Uwe Janssens, Stefan John, Christian Jung, Christian Karagiannidis, Michael Kiehl, Stefan Kluge, Alexander Koch, Matthias Kochanek, Peter Korsten, Philipp M Lepper, Martin Merkel, Ursula Müller-Werdan, Martin Neukirchen, Alexander Pfeil, Reimer Riessen, Wolfgang Rottbauer, Sebastian Schellong, Alexandra Scherg, Daniel Sedding, Katrin Singler, Marcus Thieme, Christian Trautwein, Carsten Willam, Karl Werdan
In Germany, physicians qualify for emergency medicine by combining a specialty medical training-e.g. internal medicine-with advanced training in emergency medicine according to the statutes of the State Chambers of Physicians largely based upon the Guideline Regulations on Specialty Training of the German Medical Association. Internal medicine and their associated subspecialities represent an important column of emergency medicine. For the internal medicine aspects of emergency medicine, this curriculum presents an overview of knowledge, skills (competence levels I-III) as well as behaviours and attitudes allowing for the best treatment of patients...
April 16, 2024: Medizinische Klinik, Intensivmedizin und Notfallmedizin
https://read.qxmd.com/read/38625034/highlights-in-chronic-lymphocytic-leukemia-from-the-65th-ash-annual-meeting-and-exposition-commentary
#7
JOURNAL ARTICLE
Matthew S Davids
No abstract text is available yet for this article.
February 2024: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/38625033/highlights-in-chronic-lymphocytic-leukemia-from-the-65th-ash-annual-meeting-and-exposition
#8
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
February 2024: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/38625029/highlights-in-metastatic-breast-cancer-from-the-2023-san-antonio-breast-cancer-symposium-commentary
#9
JOURNAL ARTICLE
Aditya Bardia
No abstract text is available yet for this article.
February 2024: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/38625028/highlights-in-metastatic-breast-cancer-from-the-2023-san-antonio-breast-cancer-symposium
#10
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
February 2024: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/38621469/trastuzumab-deruxtecan-in-breast-cancer
#11
REVIEW
Miguel Martín, Atanasio Pandiella, Emilio Vargas-Castrillón, Elena Díaz-Rodríguez, Teresa Iglesias-Hernangómez, Concha Martínez Cano, Inés Fernández-Cuesta, Elena Winkow, Maria Francesca Perelló
Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate (ADC) consisting of a humanised, anti-human epidermal growth factor receptor 2 (HER2) monoclonal antibody covalently linked to a topoisomerase I inhibitor cytotoxic payload (DXd). The high drug-to-antibody ratio (8:1) ensures a high DXd concentration is delivered to target tumour cells, following internalisation of T-DXd and subsequent cleavage of its tetrapeptide-based linker. DXd's membrane-permeable nature enables it to cross cell membranes and potentially exert antitumour activity on surrounding tumour cells regardless of HER2 expression...
April 13, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38621412/immunotherapy-with-genetically-engineered-t-cells-holds-promise-for-the-treatment-of-nonmalignant-diseases-in-the-dog
#12
JOURNAL ARTICLE
Nicola J Mason
The ability to genetically redirect the antigenic specificity of T cells using chimeric antigen receptors (CAR) has led to unprecedented durable clinical remissions in human patients with relapsed/refractory hematological malignancies. This remarkable advance in successful immune cell engineering has now led to investigations into the application of CAR-T-cell technology to treat nonmalignant diseases. The use of CAR-T cells to target and eliminate specific cell subsets involved in the pathogenesis of autoimmunity, fibrosis, senescence, and infectious disease represents a new direction for adoptive cell therapies...
April 16, 2024: Journal of the American Veterinary Medical Association
https://read.qxmd.com/read/38619663/minimal-residual-disease-in-systemic-light-chain-amyloidosis-a-systematic-review-and-meta-analysis
#13
JOURNAL ARTICLE
Xuefeng Li, Yan Yu, Hongbin Yu, Mengran Chen, Xin Zhang, Yu Wu
PURPOSE: Minimal residual disease (MRD) is a validated prognostic factor in several hematological malignancies. However, its role in systemic light chain (AL) amyloidosis remains controversial, and this systematic review and meta-analysis aims to fill this gap. METHODS: We searched for relevant studies on Pubmed, Embase, and Cochrane Controlled Register of Trials, nine studies involving 451 patients were included and meta-analyzed. This systematic review has been registered in PROSPERO (CRD42023494169)...
April 15, 2024: Journal of Cancer Research and Clinical Oncology
https://read.qxmd.com/read/38618451/a-rare-case-of-extranodal-natural-killer-t-cell-lymphoma-nasal-type-associated-with-hemophagocytic-lymphohistiocytosis-in-a-patient-with-recurrent-sinusitis
#14
Bryce R Christensen, Chung-Ting J Kou, Lauren E Lee
We present a rare case of hemophagocytic lymphohistiocytosis (HLH) secondary to nasal-type extranodal natural killer/T-cell lymphoma (ENKL). Nasal-type ENKL is a rare subtype of non-Hodgkin's lymphoma usually associated with Epstein-Barr virus (EBV). The patient was a 19-year-old woman who presented with facial numbness, diminished hearing, and dysgeusia. She was febrile with palatal necrosis, loss of gag reflex, and cranial nerve palsies. Labs revealed neutropenia. Broad-spectrum antimicrobials, including amphotericin, were started...
March 2024: Curēus
https://read.qxmd.com/read/38618298/thymic-adenocarcinoma-with-metastasis-to-the-left-orbit-a-case-report
#15
Renata Quevedo, Sebastian Garcia, John C Cravero, Andrew Horton, Blaine Berger, Roberto I Aguirre
We present the case of a 57-year-old female who initially presented with a chief complaint of left-sided orbital headaches and associated left eyelid swelling. Initial imaging work-up with CT head/orbit revealed soft tissue enhancement of the left orbital roof, concerning for neoplastic process (primary lymphoma versus extracranial primary tumor versus metastatic tumor). Further imaging studies with CT chest/abdomen/pelvis revealed an anterior mediastinal mass, concerning for possible thymoma versus lymphoma...
March 2024: Curēus
https://read.qxmd.com/read/38616860/chronic-hepatitis-b-and-occult-infection-in-chemotherapy-patients-evaluation-in-oncology-and-hemato-oncology-settings-the-choice-study
#16
JOURNAL ARTICLE
Nayana Sudevan, Manish Manrai, T V S V G K Tilak, Harshit Khurana, Harikrishnan Premdeep
BACKGROUND: Reactivation of hepatitis B virus (HBV) infection is a well-known risk that can occur spontaneously or following immunosuppressive therapies, including cancer chemotherapy. HBV reactivation can cause significant morbidity and even mortality, which are preventable if at-risk individuals are identified through screening and started on antiviral prophylaxis. AIM: To determine the prevalence of chronic HBV (CHB) and occult HBV infection (OBI) among oncology and hematology-oncology patients undergoing chemotherapy...
March 25, 2024: World Journal of Virology
https://read.qxmd.com/read/38615873/recent-strategies-to-overcome-breast-cancer-resistance
#17
REVIEW
Muhammad Muzamil Khan, Satya Siva Kishan Yalamarty, Bharat Ashok Rajmalani, Nina Filipczak, Vladimir P Torchilin
Breast cancer is potentially a lethal disease and a leading cause of death in women. Chemotherapy and radiotherapy are the most frequently used treatment options. Drug resistance in advanced breast cancer limits the therapeutic output of treatment. The leading cause of resistance in breast cancer is endocrine and hormonal imbalance, particularly in triple negative and HER2 positive breast cancers. The efflux of drugs due to p-gp's activity is another leading cause of resistance. Breast cancer resistant protein also contributes significantly...
April 12, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38615872/n6-methyladenosine-dependent-signaling-in-colorectal-cancer-functions-and-clinical-potential
#18
REVIEW
Shaojun Liu, Min Liu, Yuxuan Li, Qing Song
Colorectal cancer (CRC) ranks as the third most prevalent malignancy worldwide. Despite the gradual expansion of therapeutic options for CRC, its clinical management remains a formidable challenge. And, because of the current dearth of technical means for early CRC screening, most patients are diagnosed at an advanced stage. Therefore, it is imperative to develop novel diagnostic and therapeutic tools for this disease. N6-methyladenosine (m6A), the predominant RNA modification in eukaryotes, can be recognized by m6A-specific methylated reading proteins to modulate gene expression...
April 12, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38615871/the-new-era-of-lung-cancer-therapy-combining-immunotherapy-with-ferroptosis
#19
REVIEW
Yawen Li, Halahati Tuerxun, Yixin Zhao, Xingyu Liu, Xi Li, Shuhui Wen, Yuguang Zhao
Ferroptosis is an unconventional programmed cell death mode caused by phospholipid peroxidation dependent on iron. Emerging immunotherapies (especially immune checkpoint inhibitors) have the potential to enhance lung cancer patients' long-term survival. Although immunotherapy has yielded significant positive applications in some patients, there are still many mechanisms that can cause lung cancer cells to evade immunity, thus leading to the failure of targeted therapies. Immune-tolerant cancer cells are insensitive to conventional death pathways such as apoptosis and necrosis, whereas mesenchymal and metastasis-prone cancer cells are particularly vulnerable to ferroptosis, which plays a vital role in mediating immune tolerance resistance by tumors and immune cells...
April 12, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38615870/a-practical-algorithm-for-acute-myeloid-leukaemia-diagnosis-following-the-updated-2022-classifications
#20
REVIEW
Matteo Giovanni Della Porta, Giovanni Martinelli, Alessandro Rambaldi, Alessandra Santoro, Maria Teresa Voso
Disease classification of complex and heterogenous diseases, such as acute myeloid leukaemia (AML), is continuously updated to define diagnoses, appropriate treatments, and assist research and education. Recent availability of molecular profiling techniques further benefits the classification of AML. The World Health Organization (WHO) classification of haematolymphoid tumours and the International Consensus Classification of myeloid neoplasms and acute leukaemia from 2022 are two updated versions of the WHO 2016 classification...
April 12, 2024: Critical Reviews in Oncology/hematology
keyword
keyword
171374
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.